Deriva AI
AI SaaS Platform for Fast Genetic Variant Interpretation
Health Tech & Life Sciences
Private
Company Overview
Snapshot
Founded in March 2024 by Nizar Jubran, Deriva AI operates with 1–10 employees. The company secured pre-seed funding in April 2025, with Hasoub Angels participating in the round.
Business overview
Deriva AI develops an AI-based platform for genetic variant interpretation, leveraging a swarm of specialized agents to analyze scientific literature, clinical notes, and multi-omic datasets. The core technology applies continuously updated, gene-specific ACMG guidelines to produce transparent, auditable pathogenicity assessments with source citations. The platform, which includes an interactive chat interface, serves the Health Tech & Life Sciences sector, specifically targeting the.
Log in to access full profile ›Company Intelligence Q&A
- When was Deriva AI founded?
- Deriva AI was founded in March 2024.
- Who is the founder of Deriva AI?
- Nizar Jubran is the founder and CEO of Deriva AI.
- What is Deriva AI's primary sector?
- Deriva AI's primary sector is Health Tech & Life Sciences.
- What is Deriva AI's product stage?
- Deriva AI's product is currently in the Released stage, offering an AI-based platform for genetic variant interpretation with an interactive chat interface.
- Which investor participated in Deriva AI's funding round?
- In April 2025, Hasoub Angels participated in a pre-seed funding round for Deriva AI.